Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer

por Schöttle, Jakob, Chatterjee, Sampurna, Volz, Caroline, Siobal, Maike, Florin, Alexandra, Rokitta, Dennis, Hinze, Yvonne, Dietlein, Felix, Plenker, Dennis, König, Katharina, Albus, Kerstin, Heuckmann, Johannes M., Rauh, Daniel, Franz, Thomas, Neumaier, Bernd, Fuhr, Uwe, Heukamp, Lukas C., Ullrich, Roland T.
Publicado en Oncotarget (2015)